Publications by authors named "L Hami"

Context: Residential facilities for dependent elderly people have difficulties ensuring medical follow-up of their residents by general practitioners. The barriers to medical visits are well-known. Seine-Saint-Denis is particularly affected by the medical demography crisis.

View Article and Find Full Text PDF
Article Synopsis
  • Advances in omics technologies are enhancing the diagnosis of rare diseases by developing methods to identify responsible genes, particularly using transcriptomic data for detecting aberrant gene expression (AGE).
  • ABEILLE is a new method that uses variational autoencoders and decision trees to identify AGEs in RNA-seq data without needing replicates or control groups, focusing on flexibility and severity of aberrations.
  • The source code for ABEILLE is available for free on GitHub, alongside supplementary data for further insights.
View Article and Find Full Text PDF

microRNAs (miRNAs) associate with Ago proteins to post-transcriptionally silence gene expression by targeting mRNAs. To characterize the modes of miRNA-binding, we developed a novel computational framework, called optiCLIP, which considers the reproducibility of the identified peaks among replicates based on the peak overlap. We identified 98 999 binding sites for mouse and human miRNAs, from eleven Ago2 CLIP-seq datasets.

View Article and Find Full Text PDF

Introduction: Younger women are particularly affected by the increase in the incidence of vulvar cancer. The purpose of this study was to investigate how clinical characteristics differ depending on the patient´s age and what role the age of initial diagnosis plays in the prognosis. Patients andMethods: Included patients were divided into groups aged below or above 50 years.

View Article and Find Full Text PDF

Background: Pre-clinical studies suggest Xcellerated T Cells have the potential to produce a potent anti-tumor effect, restore broad immune function and reduce the risk of infectious complications in patients with CLL. Unlike other cancer settings, T cells constitute only a small fraction of CLL patients' PBMC. To generate large numbers of Xcellerated T Cells of high purity from CLL patients' PBMC, a reproducible, streamlined and cost-effective good manufacturing process (GMP) is required.

View Article and Find Full Text PDF